The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng
Po-Wei
PW
Huang
Ming-Chyi
MC
Tsai
Chang-Jer
CJ
Pan
Chun-Hung
CH
Chen
Chiao-Chicy
CC
Chiu
Chih-Chiang
CC
D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced*; D007273:Injections, Intramuscular; D007555:Isoxazoles / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D000068882:Paliperidone Palmitate; D011388:Prolactin / Q000097:blood*; D011743:Pyrimidines / Q000493:pharmacokinetics; D012107:Research Design; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D007555:Isoxazoles; D011743:Pyrimidines; D011388:Prolactin; D018967:Risperidone; D000068882:Paliperidone Palmitate